Literature DB >> 3455476

Multiple recurrence of an intracranial hemangiopericytoma.

S Palkovic1.   

Abstract

The multiple multilocular intracranial recurrence of a hemangiopericytoma (HPC) over 21 years in our patient, who has been successfully operated upon and irradiated several times, confirms the known tendency of the majority of HPCs to marked biological activity. The aggressive behavior of HPCs shows an unusually broad scale of variations. On the basis of clinical observations of this particular case, the relative or potential malignancy of HPCs is discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3455476     DOI: 10.1007/BF01782053

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  4 in total

1.  Hemangiopericytoma occurring in the meninges: case report.

Authors:  C F BEGG; R GARRET
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Hemangiopericytoma of the pituitary fossa: case report.

Authors:  J R Mangiardi; E S Flamm; H Cravioto; B Fisher
Journal:  Neurosurgery       Date:  1983-07       Impact factor: 4.654

3.  Malignant meningioma: clinical and pathological features.

Authors:  H G Thomas; C L Dolman; K Berry
Journal:  J Neurosurg       Date:  1981-12       Impact factor: 5.115

4.  The angioblastic meningioma: a reappraisal of the nosological problem. Light-, electron-microscopic, tissue, and organ culture observations.

Authors:  B C Horten; H Urich; L J Rubinstein; S R Montague
Journal:  J Neurol Sci       Date:  1977-04       Impact factor: 3.181

  4 in total
  2 in total

1.  Management of intracranial meningeal hemangiopericytomas: outcome and experience.

Authors:  K N Fountas; E Kapsalaki; M Kassam; C H Feltes; V G Dimopoulos; J S Robinson; J R Smith
Journal:  Neurosurg Rev       Date:  2006-01-04       Impact factor: 3.042

2.  Hemangiopericytoma of thoracic spine: a rare bony tumor.

Authors:  Raj Kumar; Vivek Kumar Vaid; Vimal Kumar; Samir Kumar Kalra
Journal:  Childs Nerv Syst       Date:  2007-05-31       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.